United Therapeutics (UTHR) Stock

UTHR has strong advantages, such as high capital returns and effective profit reinvestment, which create a positive outlook. In the third quarter of fiscal year 2024, United Therapeutics reported impressive growth in its main products, with Tyvaso, Orenitram, and Unituxin all showing significant year-on-year increases. I estimate that the company's earnings could grow by 40% in the next 2-3 years.

United Therapeutics is a top company in treating pulmonary arterial hypertension (PAH), mainly due to its main product, Tyvaso, which generates most of its income. The company is also making advancements in organ transplants and bioengineered organs, such as xenotransplantation and ex vivo lung perfusion, which could change the industry. However, ongoing legal disputes, especially with Liquidia, pose risks to United Therapeutics' intellectual property and could impact its position in the PAH market.

Since I recommended buying United Therapeutics Corporation's stock in 2020, it has increased by more than 300%, mainly due to strong sales of Tyvaso DPI and other treatments for pulmonary arterial hypertension (PAH). Even with competition from generic drugs, the company has shown strength by using legal strategies and developing new products to safeguard and enhance its income. The company's future success will depend on increasing the market for Tyvaso DPI and progressing its pipeline, which includes exciting treatments for idiopathic pulmonary fibrosis (IPF) and innovative organ transplant technologies.

No matter if you invest in value, growth, or momentum, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

UTHR has announced better-than-expected results for the third quarter of 2024, thanks to high demand for its treprostinil drugs, particularly Tyvaso.

United Therapeutics Corporation (NASDAQ:UTHR) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 9:00 AM ET. Key company participants include Dewey Steadman, Martine Rothblatt, Michael Benkowitz, James Edgemond, and Leigh Peterson. The call will also feature analysts from various firms, and the operator for the event is Dave.

While the revenue and earnings per share (EPS) for United Therapeutics (UTHR) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

In addition to looking at analysts' predictions for United Therapeutics' (UTHR) revenue and profits, it's important to assess forecasts for some of its main metrics. This will help us understand how the company may have performed in the quarter that ended in September 2024.